A 65-year-old never-smoking white male with advanced sarcomatoid NSCLC harboring a MET exon 14 skipping mutation and with a PD-L1 tumor proportion score of 80% was initiated on combination chemotherapy plus ICI therapy after progression on a MET inhibitor. This evidence concerns the gene MET and neoplasm.